Logo image of LJPC

LA JOLLA PHARMACEUTICAL CO (LJPC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LJPC - US5034596040 - Common Stock

6.22 USD
0 (0%)
Last: 8/19/2022, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, LJPC scores 2 out of 10 in our fundamental rating. LJPC was compared to 530 industry peers in the Biotechnology industry. The financial health of LJPC is average, but there are quite some concerns on its profitability. LJPC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LJPC has reported negative net income.
LJPC Yearly Net Income VS EBIT VS OCF VS FCFLJPC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 -50M -100M -150M

1.2 Ratios

Industry RankSector Rank
ROA 3.99%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LJPC Yearly ROA, ROE, ROICLJPC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 200 -200 -400

1.3 Margins

Industry RankSector Rank
OM -5.53%
PM (TTM) 8.54%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LJPC Yearly Profit, Operating, Gross MarginsLJPC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

LJPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LJPC has less shares outstanding
Compared to 1 year ago, LJPC has a worse debt to assets ratio.
LJPC Yearly Shares OutstandingLJPC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
LJPC Yearly Total Debt VS Total AssetsLJPC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -12.76, we must say that LJPC is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for LJPC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.76
ROIC/WACCN/A
WACC9.48%
LJPC Yearly LT Debt VS Equity VS FCFLJPC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M -100M -150M

2.3 Liquidity

A Current Ratio of 4.02 indicates that LJPC has no problem at all paying its short term obligations.
A Quick Ratio of 3.52 indicates that LJPC has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 3.52
LJPC Yearly Current Assets VS Current LiabilitesLJPC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

LJPC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
LJPC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -33.79%.
LJPC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 161.44% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
Revenue 1Y (TTM)-33.79%
Revenue growth 3Y95.98%
Revenue growth 5Y161.44%
Sales Q2Q%-34.35%

3.2 Future

The Earnings Per Share is expected to grow by 38.81% on average over the next years. This is a very strong growth
LJPC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.65% yearly.
EPS Next Y-92.84%
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%
EPS Next 5Y38.81%
Revenue Next Year-31.93%
Revenue Next 2Y-9.19%
Revenue Next 3Y-0.71%
Revenue Next 5Y6.65%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LJPC Yearly Revenue VS EstimatesLJPC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
LJPC Yearly EPS VS EstimatesLJPC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LJPC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 26.51, which means the current valuation is very expensive for LJPC.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.57, LJPC is valued at the same level.
Industry RankSector Rank
PE N/A
Fwd PE 26.51
LJPC Price Earnings VS Forward Price EarningsLJPC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150 -200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -120.41
LJPC Per share dataLJPC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A cheap valuation may be justified as LJPC's earnings are expected to decrease with -5.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%

More info and screens

0

5. Dividend

5.1 Amount

LJPC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LA JOLLA PHARMACEUTICAL CO

NASDAQ:LJPC (8/19/2022, 8:00:02 PM)

6.22

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-15 2022-08-15/bmo
Earnings (Next)11-02 2022-11-02
Inst Owners0%
Inst Owner Change0%
Ins Owners6.25%
Ins Owner Change0%
Market Cap158.96M
Revenue(TTM)46.49M
Net Income(TTM)3.97M
Analysts43.33
Price Target6.35 (2.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 26.51
P/S 3.42
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -120.41
EPS(TTM)-0.03
EYN/A
EPS(NY)0.23
Fwd EY3.77%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.82
BVpS-2.72
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 3.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -5.53%
PM (TTM) 8.54%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 3.52
Altman-Z -12.76
F-Score7
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
EPS Next Y-92.84%
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%
EPS Next 5Y38.81%
Revenue 1Y (TTM)-33.79%
Revenue growth 3Y95.98%
Revenue growth 5Y161.44%
Sales Q2Q%-34.35%
Revenue Next Year-31.93%
Revenue Next 2Y-9.19%
Revenue Next 3Y-0.71%
Revenue Next 5Y6.65%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

LA JOLLA PHARMACEUTICAL CO / LJPC FAQ

What is the ChartMill fundamental rating of LA JOLLA PHARMACEUTICAL CO (LJPC) stock?

ChartMill assigns a fundamental rating of 4 / 10 to LJPC.


Can you provide the valuation status for LA JOLLA PHARMACEUTICAL CO?

ChartMill assigns a valuation rating of 3 / 10 to LA JOLLA PHARMACEUTICAL CO (LJPC). This can be considered as Overvalued.


Can you provide the profitability details for LA JOLLA PHARMACEUTICAL CO?

LA JOLLA PHARMACEUTICAL CO (LJPC) has a profitability rating of 6 / 10.


How financially healthy is LA JOLLA PHARMACEUTICAL CO?

The financial health rating of LA JOLLA PHARMACEUTICAL CO (LJPC) is 3 / 10.


What is the earnings growth outlook for LA JOLLA PHARMACEUTICAL CO?

The Earnings per Share (EPS) of LA JOLLA PHARMACEUTICAL CO (LJPC) is expected to decline by -92.84% in the next year.